Technology Briefing

Double blind on Fabry

When more than one company is vying to be first to market in an orphan indication, comparative data are likely to weigh heavily in the minds of investors. But in the case of Genzyme General and Transkaryotic Therapies Inc., which are developing enzyme replacement therapies to treat Fabry disease, such an apples-to-apples comparison is impossible because the companies are not giving out any fruit.

Neither company has